Antiestrogenic effects of the novel sphingosine kinase-2 inhibitor ABC294640

Endocrinology

Volumn 151, Issue 11, 2010, Pages 5124-5135

  Antoon, James W ^a   White, Martin D ^a   Meacham, William D ^a   Slaughter, Evelyn M ^a   Muir, Shannon E ^a   Elliott, Steven ^a   Rhodes, Lyndsay V ^a   Ashe, Hasina B ^b   Wiese, Thomas E ^b   Smith, Charles D ^c   Burow, Matthew E ^a   Beckman, Barbara S ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b XAVIER UNIVERSITY OF LOUISIANA   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4 CHLOROPHENYL)ADAMANTANE 1 CARBOXYLIC ACID (PYRIDIN 4 YLMETHYL)AMIDE; ABC 294640; ENZYME INHIBITOR; ESTROGEN; ESTROGEN RECEPTOR BETA; PROGESTERONE RECEPTOR; SPHINGOSINE KINASE 2; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG; 3 (4 CHLOROPHENYL) ADAMANTANE 1 CARBOXYLIC ACID (PYRIDIN 4 YLMETHYL)AMIDE; 3-(4-CHLOROPHENYL)-ADAMANTANE-1-CARBOXYLIC ACID (PYRIDIN-4-YLMETHYL)AMIDE; ADAMANTANE; DRUG DERIVATIVE; ESTRADIOL; ESTROGEN RECEPTOR; PHOSPHOTRANSFERASE; PYRIDINE DERIVATIVE; SPHINGOSINE KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CELL; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG RECEPTOR BINDING; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GENE CONTROL; GENETIC TRANSCRIPTION; HORMONE ACTION; IMMUNOHISTOCHEMISTRY; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR VOLUME; WEIGHT REDUCTION; ANALYSIS OF VARIANCE; ANIMAL; CELL CULTURE; CELL LINE; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION; GENETICS; HUMAN; METABOLISM; MOUSE; PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADAMANTANE; ANALYSIS OF VARIANCE; ANIMALS; BLOTTING, WESTERN; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; ESTRADIOL; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; PHOSPHORYLATION; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); PYRIDINES; RECEPTORS, ESTROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 78049490720     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2010-0420     Document Type: Article

References (56)

1. Fuqua SA, Cui Y 2002 Targeting the estrogen receptor in clinical breast cancer. Breast Dis 15:3-11
2. Nava VE, Hobson JP, Murthy S, Milstien S, Spiegel S 2002 Sphingosine kinase type 1 promotes estrogen-dependent tumorigenesis of breast cancer MCF-7 cells. Exp Cell Res 281:115-127
3. Burow ME, Weldon CB, Collins-Burow BM, Ramsey N, McKee A, Klippel A, McLachlan JA, Clejan S, Beckman BS 2000 Cross-talk between phosphatidylinositol 3-kinase and sphingomyelinase pathways as a mechanism for cell survival/death decisions. J Biol Chem 275:9628-9635
4. Sukocheva O, Wang L, Verrier E, Vadas MA, Xia P 2009 Restoring endocrine response in breast cancer cells by inhibition of the sphingosine kinase-1 signaling pathway. Endocrinology 150:4484-4492
5. Hong G, Baudhuin LM, Xu Y 1999 Sphingosine-1-phosphate modulates growth and adhesion of ovarian cancer cells. FEBS Lett 460:513-518
6. Gratschev D, Löf C, Heikkilä J, Björkbom A, Sukumaran P, Hinkkanen A, Slotte JP, Törnquist K 2009 Sphingosine kinase as a regulator of calcium entry through autocrine sphingosine 1-phosphate signaling in thyroid FRTL-5 cells. Endocrinology 150:5125-5134
7. Balthasar S, Samulin J, Ahlgren H, Bergelin N, Lundqvist M, Toescu EC, Eggo MC, Törnquist K 2006 Sphingosine 1-phosphate receptor expression profile and regulation of migration in human thyroid cancer cells. Biochem J 398:547-556 (Pubitemid 44453400)
8. Meacham WD, Antoon JW, Burow ME, Struckhoff AP, Beckman BS 2009 Sphingolipids as determinants of apoptosis and chemoresistance in the MCF-7 cell model system. Exp Biol Med (Maywood) 234:1253-1263
9. Hannun YA, Obeid LM 2008 Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev 9:139-150
10. Lucki NC, Sewer MB 2008 Multiple roles for sphingolipids in steroid hormone biosynthesis. Subcell Biochem 49:387-412
11. Lucki NC, Sewer MB 2010 The interplay between bioactive sphingolipids and steroid hormones. Steroids 75:390-399
12. Olivera A, Spiegel S 2001 Sphingosine kinase: a mediator of vital cellular functions. Prostaglandins 64:123-134 (Pubitemid 32452286)
13. Baudhuin LM, Cristina KL, Lu J, Xu Y 2002 Akt activation induced by lysophosphatidic acid and sphingosine-1-phosphate requires both mitogen-activated protein kinase kinase and p38 mitogen-activated protein kinase and is cell-line specific. Mol Pharmacol 62:660-671 (Pubitemid 36329385)
14. Kim DS, Hwang ES, Lee JE, Kim SY, Park KC 2003 Sphingosine-1-phosphate promotes mouse melanocyte survival via ERK and Akt activation. Cell Signal 15:919-926
15. Weldon CB, Parker AP, Patten D, Elliott S, Tang Y, Frigo DE, Dugan CM, Coakley EL, Butler NN, Clayton JL, Alam J, Curiel TJ, Beckman BS, Jaffe BM, Burow ME 2004 Sensitization of apoptotically-resistant breast carcinoma cells to TNF and TRAIL by inhibition of p38 mitogen-activated protein kinase signaling. Int J Oncol 24:1473-1480
16. Weldon CB, Scandurro AB, Rolfe KW, Clayton JL, Elliott S, Butler NN, Melnik LI, Alam J, McLachlan JA, Jaffe BM, Beckman BS, Burow ME 2002 Identification of mitogen-activated protein kinase kinase as a chemoresistant pathway in MCF-7 cells by using gene expression microarray. Surgery 132:293-301 (Pubitemid 35024776)
17. Filardo EJ 2002 Epidermal growth factor receptor (EGFR) transactivation by estrogen via the G-protein-coupled receptor, GPR30: a novel signaling pathway with potential significance for breast cancer. J Steroid Biochem Mol Biol 80:231-238
18. Sukocheva OA, Wang L, Albanese N, Pitson SM, Vadas MA, Xia P 2003 Sphingosine kinase transmits estrogen signaling in human breast cancer cells. Mol Endocrinol 17:2002-2012
19. Sukocheva O, Wang L, Verrier E, Vadas MA, Xia P 2009 Restoring endocrine response in breast cancer cells by inhibition of the sphingosine kinase-1 signaling pathway. Endocrinology 150:4184-4192
20. Xia P, Wang L, Moretti PA, Albanese N, Chai F, Pitson SM, D'Andrea RJ, Gamble JR, Vadas MA 2002 Sphingosine kinase interacts with TRAF2 and dissects tumor necrosis factor-α signaling. J Biol Chem 277:7996-8003
21. Takabe K, Kim RH, Allegood JC, Mitra P, Ramachandran S, Nagahashi M, Harikumar KB, Hait NC, Milstien S, Spiegel S 2010 Estradiol induces export of sphingosine 1-phosphate from breast cancer cells via ABCC1 and ABCG2. J Biol Chem 285:10477-10486
22. French KJ, Zhuang Y, Maines LW, Gao P, Wang W, Beljanski V, Upson JJ, Green CL, Keller SN, Smith CD 2010 Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2. J Pharmacol Exp Ther 333:129-139
23. Raymond MN, Bole-Feysot C, Banno Y, Tanfin Z, Robin P 2006 Endothelin-1 inhibits apoptosis through a sphingosine kinase 1-dependent mechanism in uterine leiomyoma ELT3 cells. Endocrinology 147:5873-5882 (Pubitemid 44833504)
24. Morales A, Fernandez-Checa JC 2007 Pharmacological modulation of sphingolipids and role in disease and cancer cell biology. Mini Rev Med Chem 7:371-382 (Pubitemid 46681760)
25. Gangoiti P, Camacho L, Arana L, Ouro A, Granado MH, Brizuela L, Casas J, Fabrias G, Abad JL, Delgado A, Gomez-Munoz A 2010 Control of metabolism and signaling of simple bioactive sphingolipids: Implications in disease. Prog Lipid Res
26. Antoon JW, Liu J, Gestaut MM, Burow ME, Beckman BS, Foroozesh M 2009 Design, synthesis, and biological activity of a family of novel ceramide analogues in chemoresistant breast cancer cells. J Med Chem 52:5748-5752
27. Burow ME, Weldon CB, Tang Y, Navar GL, Krajewski S, Reed JC, Hammond TG, Clejan S, Beckman BS 1998 Differences in susceptibility to tumor necrosis factor α-induced apoptosis among MCF-7 breast cancer cell variants. Cancer Res 58:4940-4946 (Pubitemid 28503694)
28. Boué SM, Tilghman SL, Elliott S, Zimmerman MC, Williams KY, Payton-Stewart F, Miraflor AP, Howell MH, Shih BY, Carter-Wientjes CH, Segar C, Beckman BS, Wiese TE, Cleveland TE, McLachlan JA, Burow ME 2009 Identification of the potent phytoestrogen glycinol in elicited soybean (Glycine max). Endocrinology 150:2446-2453
29. Rhodes LV, Muir SE, Elliott S, Guillot LM, Antoon JW, Penfornis P, Tilghman SL, Salvo VA, Fonseca JP, Lacey MR, Beckman BS, McLachlan JA, Rowan BG, Pochampally R, Burow ME 2010 Adult human mesenchymal stem cells enhance breast tumorigenesis and promote hormone independence. Breast Cancer Res Treat 121:293-300
30. Struckhoff AP, Bittman R, Burow ME, Clejan S, Elliott S, Hammond T, Tang Y, Beckman BS 2004 Novel ceramide analogs as potential chemotherapeutic agents in breast cancer. J Pharmacol Exp Ther 309:523-532
31. Bratton MR, Frigo DE, Vigh-Conrad KA, Fan D, Wadsworth S, McLachlan JA, Burow ME 2009 Organochlorine-mediated potentiation of the general coactivator p300 through p38 mitogen-activated protein kinase. Carcinogenesis 30:106-113
32. Salvo VA, Boué SM, Fonseca JP, Elliott S, Corbitt C, Collins-Burow BM, Curiel TJ, Srivastav SK, Shih BY, Carter-Wientjes C, Wood CE, Erhardt PW, Beckman BS, McLachlan JA, Cleveland TE, Burow ME 2006 Antiestrogenic glyceollins suppress human breast and ovarian carcinoma tumorigenesis. Clin Cancer Res 12:7159-7164
33. Rao AK, Ziegler YS, McLeod IX, Yates JR, Nardulli AM 2008 Effects of Cu/Zn superoxide dismutase on estrogen responsiveness and oxidative stress in human breast cancer cells. Mol Endocrinol 22:1113-1124
34. Bielawski J, Szulc ZM, Hannun YA, Bielawska A 2006 Simultaneous quantitative analysis of bioactive sphingolipids by high-performance liquid chromatography-tandem mass spectrometry. Methods 39:82-91
35. Brown JM, Wouters BG 1999 Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res 59:1391-1399
36. Michalakis J, Georgatos SD, de Bree E, Polioudaki H, Romanos J, Georgoulias V, Tsiftsis DD, Theodoropoulos PA 2007 Short-term exposure of cancer cells to micromolar doses of paclitaxel, with or without hyperthermia, induces long-term inhibition of cell proliferation and cell death in vitro. Ann Surg Oncol 14:1220-1228
37. Weldon CB, Burow ME, Rolfe KW, Clayton JL, Jaffe BM, Beckman BS 2001 NF-κB-mediated chemoresistance in breast cancer cells. Surgery 130:143-150 (Pubitemid 32721661)
38. Starborg M, Gell K, Brundell E, Hoog C 1996 The murine Ki-67 cell proliferation antigen accumulates in the nucleolar and heterochromatic regions of interphase cells and at the periphery of the mitotic chromosomes in a process essential for cell cycle progression. J Cell Sci 109(Pt 1):143-153 (Pubitemid 26037936)
39. Beresford MJ, Wilson GD, Makris A 2006 Measuring proliferation in breast cancer: practicalities and applications. Breast Cancer Res 8:216
40. Stuart-Harris R, Caldas C, Pinder SE, Pharoah P 2008 Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients. Breast 17:323-334
41. Ruckhäberle E, Rody A, Engels K, Gaetje R, von Minckwitz G, Schiffmann S, Grösch S, Geisslinger G, Holtrich U, Karn T, Kaufmann M 2008 Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer. Breast Cancer Res Treat 112:41-52
42. Kohama T, Olivera A, Edsall L, Nagiec MM, Dickson R, Spiegel S 1998 Molecular cloning and functional characterization of murine sphingosine kinase. J Biol Chem 273:23722-23728 (Pubitemid 28435703)
43. Billich A, Bornancin F, Dévay P, Mechtcheriakova D, Urtz N, Baumruker T 2003 Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases. J Biol Chem 278:47408-47415
44. Kihara A, Anada Y, Igarashi Y 2006 Mouse sphingosine kinase isoforms SPHK1a and SPHK1b differ in enzymatic traits including stability, localization, modification, and oligomerization. J Biol Chem 281:4532-4539
45. Fukuda Y, Kihara A, Igarashi Y 2003 Distribution of sphingosine kinase activity in mouse tissues: contribution of SPHK1. Biochem Biophys Res Commun 309:155-160
46. Liu H, Sugiura M, Nava VE, Edsall LC, Kono K, Poulton S, Milstien S, Kohama T, Spiegel S 2000 Molecular cloning and functional characterization of a novel mammalian sphingosine kinase type 2 isoform. J Biol Chem 275:19513-19520 (Pubitemid 30441543)
47. Okada T, Ding G, Sonoda H, Kajimoto T, Haga Y, Khosrowbeygi A, Gao S, Miwa N, Jahangeer S, Nakamura S 2005 Involvement of N-terminal-extended form of sphingosine kinase 2 in serum-dependent regulation of cell proliferation and apoptosis. J Biol Chem 280:36318-36325 (Pubitemid 41633905)
48. Liu H, Toman RE, Goparaju SK, Maceyka M, Nava VE, Sankala H, Payne SG, Bektas M, Ishii I, Chun J, Milstien S, Spiegel S 2003 Sphingosine kinase type 2 is a putative BH3-only protein that induces apoptosis. J Biol Chem 278:40330-40336
49. Maceyka M, Sankala H, Hait NC, Le Stunff H, Liu H, Toman R, Collier C, Zhang M, Satin LS, Merrill Jr AH, Milstien S, Spiegel S 2005 SphK1 and SphK2, sphingosine kinase isoenzymes with opposing functions in sphingolipid metabolism. J Biol Chem 280:37118-37129
50. Sankala HM, Hait NC, Paugh SW, Shida D, Lépine S, Elmore LW, Dent P, Milstien S, Spiegel S 2007 Involvement of sphingosine kinase 2 in p53-independent induction of p21 by the chemotherapeutic drug doxorubicin. Cancer Res 67:10466-10474
51. Beljanski V, Knaak C, Smith CD 2010 A novel sphingosine kinase inhibitor induces autophagy in tumor cells. J Pharmacol Exp Ther 333:454-464
52. Hait NC, Allegood J, Maceyka M, Strub GM, Harikumar KB, Singh SK, Luo C, Marmorstein R, Kordula T, Milstien S, Spiegel S 2009 Regulation of histone acetylation in the nucleus by sphingosine-1- phosphate. Science 325:1254-1257
53. Duong BN, Elliott S, Frigo DE, Melnik LI, Vanhoy L, Tomchuck S, Lebeau HP, David O, Beckman BS, Alam J, Bratton MR, McLachlan JA, Burow ME 2006 AKT regulation of estrogen receptor β transcriptional activity in breast cancer. Cancer Res 66:8373-8381
54. Frigo DE, Basu A, Nierth-Simpson EN, Weldon CB, Dugan CM, Elliott S, Collins-Burow BM, Salvo VA, Zhu Y, Melnik LI, Lopez GN, Kushner PJ, Curiel TJ, Rowan BG, McLachlan JA, Burow ME 2006 p38 mitogen-activated protein kinase stimulates estrogen-mediated transcription and proliferation through the phosphorylation and potentiation of the p160 coactivator glucocorticoid receptor-interacting protein 1. Mol Endocrinol 20:971-983
55. Kuske B, Naughton C, Moore K, Macleod KG, Miller WR, Clarke R, Langdon SP, Cameron DA 2006 Endocrine therapy resistance can be associated with high estrogen receptor α (ERα) expression and reduced ERα phosphorylation in breast cancer models. Endocr Relat Cancer 13:1121-1133 (Pubitemid 46212567)
56. Xia P, Wang L, Gamble JR, Vadas MA 1999 Activation of sphingosine kinase by tumor necrosis factor-α inhibits apoptosis in human endothelial cells. J Biol Chem 274:34499-34505 (Pubitemid 129511798)